NCT03838692View on ClinicalTrials.gov

Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 26, 2019

Primary Completion Date

June 14, 2021

Study Completion Date

June 14, 2021

Conditions
Medullary Thyroid Cancer
Interventions
DRUG

Ponatinib

A daily oral dose at 30 mg.

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Antonio Fojo

OTHER

NCT03838692 - Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Biotech Hunter | Biotech Hunter